Rethinking Projects:
Rethinking the management of brain disorders
Despite improvements and innovation in recent years, people living with brain conditions, neurological and mental alike, face variations in access to optimal treatment and care. There is a lot about brain disorders that is not fully understood and the high-quality care and support needed by people living with these conditions is often unavailable.
The aim of the Rethinking Projects is to develop policy priorities around challenges in brain disorders and present a consensus on what needs to be achieved to resolve the most pressing challenges in brain conditions, today and in the future. There is a clear need to rethink the management of the brain disorders and redesign the care pathways to ensure optimal treatment and care for all people living with brain disorders in Europe.
Objectives of the Rethinking projects
Develop an evidence-based policy narrative on brain conditions to help create a sustained policy response in Europe
Draw from our findings practical solutions on how to implement policy recommendations
Raise awareness about the importance of optimising the management of brain conditions
Partners of the Rethinking projects
The RETHINKING projects are supported through financial contributions from Biogen, Bristol Myers Squibb, Celgene, the European Federation of Pharmaceutical Industries and Associations, Janssen, Lilly, Merck, Novartis, Pfizer and Sanofi.
All outputs are non-promotional and not specific to any particular treatment or therapy.